Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lisa Buvall is active.

Publication


Featured researches published by Lisa Buvall.


Journal of Clinical Investigation | 2013

Inhibition of the TRPC5 ion channel protects the kidney filter

Thomas Schaldecker; Sookyung Kim; Constantine Tarabanis; Dequan Tian; Samy Hakroush; Philip Castonguay; Wooin Ahn; Hanna Wallentin; Hans Heid; Corey R. Hopkins; Craig W. Lindsley; Antonio Riccio; Lisa Buvall; Astrid Weins; Anna Greka

An intact kidney filter is vital to retention of essential proteins in the blood and removal of waste from the body. Damage to the filtration barrier results in albumin loss in the urine, a hallmark of cardiovascular disease and kidney failure. Here we found that the ion channel TRPC5 mediates filtration barrier injury. Using Trpc5-KO mice, a small-molecule inhibitor of TRPC5, Ca2+ imaging in isolated kidney glomeruli, and live imagining of podocyte actin dynamics, we determined that loss of TRPC5 or its inhibition abrogates podocyte cytoskeletal remodeling. Inhibition or loss of TRPC5 prevented activation of the small GTP-binding protein Rac1 and stabilized synaptopodin. Importantly, genetic deletion or pharmacologic inhibition of TRPC5 protected mice from albuminuria. These data reveal that the Ca2+-permeable channel TRPC5 is an important determinant of albuminuria and identify TRPC5 inhibition as a therapeutic strategy for the prevention or treatment of proteinuric kidney disease.


Journal of The American Society of Nephrology | 2014

Role of Podocyte B7-1 in Diabetic Nephropathy

Paolo Fiorina; Andrea Vergani; Roberto Bassi; Monika A. Niewczas; Mehmet M. Altintas; Marcus G. Pezzolesi; Francesca D’Addio; Melissa Chin; Sara Tezza; Moufida Ben Nasr; Deborah Mattinzoli; Masami Ikehata; Domenico Corradi; Valérie Schumacher; Lisa Buvall; Chih-Chuan Yu; Jer-Ming Chang; Stefano La Rosa; Giovanna Finzi; Anna Solini; Flavio Vincenti; Maria Pia Rastaldi; Jochen Reiser; Andrzej S. Krolewski; Peter Mundel; Mohamed H. Sayegh

Podocyte injury and resulting albuminuria are hallmarks of diabetic nephropathy, but targeted therapies to halt or prevent these complications are currently not available. Here, we show that the immune-related molecule B7-1/CD80 is a critical mediator of podocyte injury in type 2 diabetic nephropathy. We report the induction of podocyte B7-1 in kidney biopsy specimens from patients with type 2 diabetes. Genetic and epidemiologic studies revealed the association of two single nucleotide polymorphisms at the B7-1 gene with diabetic nephropathy. Furthermore, increased levels of the soluble isoform of the B7-1 ligand CD28 correlated with the progression to ESRD in individuals with type 2 diabetes. In vitro, high glucose conditions prompted the phosphatidylinositol 3 kinase-dependent upregulation of B7-1 in podocytes, and the ectopic expression of B7-1 in podocytes increased apoptosis and induced disruption of the cytoskeleton that were reversed by the B7-1 inhibitor CTLA4-Ig. Podocyte expression of B7-1 was also induced in vivo in two murine models of diabetic nephropathy, and treatment with CTLA4-Ig prevented increased urinary albumin excretion and improved kidney pathology in these animals. Taken together, these results identify B7-1 inhibition as a potential therapeutic strategy for the prevention or treatment of diabetic nephropathy.


Clinical and Experimental Immunology | 2006

Phenotype of early cardiomyopathic changes induced by active immunization of rats with a synthetic peptide corresponding to the second extracellular loop of the human β1-adrenergic receptor

Lisa Buvall; E. Bollano; J. Chen; W. Shultze; Michael Fu

In the failing human heart, due to idiopathic dilated cardiomyopathy, it has been suggested that the β1‐adrenergic receptor (β1AR) is a potential pathogenic autoantigen. The aim of the present study was to investigate whether immunization of rats with a synthetic peptide corresponding to the second extracellular loop of the β1AR (β1AR ECII) was able to induce the early stage of cardiomyopathy and also to investigate immunological and receptor functional parameters at a transcriptional level to permit insights into the autoimmune mechanism in cardiomyopathy. Eleven Whistar Fur rats were immunized with a β1AR ECII peptide (H26R) once a month during 12 months and seven control rats were injected with vehicle according to the same procedure used for the immunized group. Cardiac function, β1AR autoantibodies and their functional effects on cardiomyocytes were analysed. β1AR receptor signalling, immunological and cardiomyocyte stretch markers were determined on transcriptional level. In H26R immunized rats, β1AR autoantibodies were shown to be present and functionally active, cardiac functions in terms of fractional shortening were decreased and β1‐adrenergic receptor kinase (GRK2) mRNA were increased compared with the control group. These data have shown that immunization of rats with a putative antigenic peptide was able to induce an early stage phenotype of cardiomyopathy in the form of cardiac dysfunction and up‐regulation of GRK2 as the first step in the desensitization process of the β1AR, implying the pathological importance of the β1AR autoantibody.


Nature Communications | 2013

Proteasomal degradation of Nck1 but not Nck2 regulates RhoA activation and actin dynamics

Lisa Buvall; Priyanka Rashmi; Esther Lopez-Rivera; Svetlana Andreeva; Astrid Weins; Hanna Wallentin; Anna Greka; Peter Mundel

The ubiquitously expressed adapter proteins Nck1/2 interact with a multitude of effector molecules to regulate diverse cellular functions including cytoskeletal dynamics. Here we show that Nck1, but not Nck2, is a substrate of c-Cbl-mediated ubiquitination. We uncover lysine 178 in Nck1 as the evolutionarily conserved ubiquitin acceptor site. We previously reported that synaptopodin, a proline-rich actin-binding protein, induces stress fibres by blocking the Smurf1-mediated ubiquitination of RhoA. We now find that synaptopodin competes with c-Cbl for binding to Nck1, which prevents the ubiquitination of Nck1 by c-Cbl. Gene silencing of c-Cbl restores Nck1 protein abundance and stress fibres in synaptopodin knockdown cells. Similarly, expression of c-Cbl-resistant Nck1(K178R) or Nck2 containing the SH3 domain 2 of Nck1 restores stress fibres in synaptopodin-depleted podocytes through activation of RhoA signalling. These findings reveal proteasomal regulation as a key factor in the distinct and non-redundant effects of Nck on RhoA-mediated actin dynamics.


Free Radical Biology and Medicine | 2008

The fungal nephrotoxin orellanine simultaneously increases oxidative stress and down-regulates cellular defenses

Ulf Nilsson; Jenny Nyström; Lisa Buvall; Kerstin Ebefors; Anna Björnson-Granqvist; Johan Holmdahl; Börje Haraldsson

Confusion of various nephrotoxic Cortinarius species with edible mushrooms occurs every year throughout Europe and North America. The toxin, orellanine (OR), accumulates selectively in renal tubular epithelium with ensuing renal failure after several days as the only clinical manifestation. This study was performed to clarify the mechanisms behind the kidney damage. Sprague-Dawley rats, 100 g bw, received various doses of purified OR ip (0-5 mg/kg bw). One week later, renal function (GFR) was determined (51Cr-EDTA), ascorbyl radicals in venous blood were analyzed using electron spin resonance, and oxidative protein damage was evaluated immunohistochemically. One OR-treated group (3.5 mg/kg) simultaneously received superoxide dismutase (SOD) targeted to tubular epithelium (HC-SOD; 10 mg/kg ip daily for 5 days). RT-PCR was used for analysis of mRNA expression of genes related to oxidative stress. OR caused a dose-dependent decrease in GFR, paralleled by increased levels of ascorbyl radicals and oxidative protein damage. Antioxidant treatment with HC-SOD decreased renal function even more and also increased tissue damage and mortality. Renal mRNA levels for key components in the antioxidative defense were strongly decreased, whereas those for several cytokines were increased. The data strongly suggest that OR nephrotoxicity in vivo is mediated by oxidative stress, including a virtual shutdown of important antioxidative enzymes. We interpret the unexpected effect of HC-SOD in terms of unbalanced SOD and catalase levels in the presence of OR, leading to massive generation of *OH and cell death.


Journal of The American Society of Nephrology | 2017

Synaptopodin Is a Coincidence Detector of Tyrosine versus Serine/Threonine Phosphorylation for the Modulation of Rho Protein Crosstalk in Podocytes

Lisa Buvall; Hanna Wallentin; Jonas Sieber; Svetlana Andreeva; Hoon Young Choi; Peter Mundel; Anna Greka

Tyrosine and serine/threonine signal-transduction pathways influence many aspects of cell behavior, including the spatial and temporal regulation of the actin cytoskeleton. However, little is known about how input from diverse tyrosine and serine/threonine kinases is integrated to control Rho protein crosstalk and actin remodeling, which are critically important in podocyte health and disease. Here we unveil the proteolytically-regulated, actin organizing protein synaptopodin as a coincidence detector of tyrosine versus serine/threonine phosphorylation. We show that serine/threonine and tyrosine kinases duel for synaptopodin stability versus degradation. EGFR/Src-mediated tyrosine phosphorylation of synaptopodin in podocytes promotes binding to the serine/threonine phosphatase calcineurin. This leads to the loss of 14-3-3 binding, resulting in synaptopodin degradation, Vav2 activation, enhanced Rac1 signaling, and ultimate loss of stress fibers. Our studies reveal how synaptopodin, a single proteolytically-controlled protein, integrates antagonistic tyrosine versus serine/threonine phosphorylation events for the dynamic control of the actin cytoskeleton in podocytes.


American Journal of Physiology-renal Physiology | 2016

Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation

Johannes Elvin; Lisa Buvall; Annika Lindskog Jonsson; Anna Granqvist; Emelie Lassén; Lovisa Bergwall; Jenny Nyström; Börje Haraldsson

Drugs containing adrenocorticotropic hormone have been used as therapy for patients with nephrotic syndrome. We have previously shown that adrenocorticotropic hormone and a selective agonist for the melanocortin 1 receptor (MC1R) exert beneficial actions in experimental membranous nephropathy with reduced proteinuria, reduced oxidative stress, and improved glomerular morphology and function. Our hypothesis is that MC1R activation in podocytes elicits beneficial effects by promoting stress fibers and maintaining podocyte viability. To test the hypothesis, we cultured podocytes and used highly specific agonists for MC1R. Podocytes were subjected to the nephrotic-inducing agent puromycin aminonucleoside, and downstream effects of MC1R activation on podocyte survival, antioxidant defense, and cytoskeleton dynamics were studied. To increase the response and enhance intracellular signals, podocytes were transduced to overexpress MC1R. We showed that puromycin promotes MC1R expression in podocytes and that activation of MC1R promotes an increase of catalase activity and reduces oxidative stress, which results in the dephosphorylation of p190RhoGAP and formation of stress fibers through RhoA. In addition, MC1R agonists protect against apoptosis. Together, these mechanisms protect the podocyte against puromycin. Our findings strongly support the hypothesis that selective MC1R-activating agonists protect podocytes and may therefore be useful to treat patients with nephrotic syndromes commonly considered as podocytopathies.


Oncotarget | 2017

Orellanine specifically targets renal clear cell carcinoma

Lisa Buvall; Heidi Hedman; Alina Khramova; Deman Najar; Lovisa Bergwall; Kerstin Ebefors; Carina Sihlbom; Sven Lundstam; Anders Herrmann; Hanna Wallentin; Emelie Roos; Ulf Nilsson; Martin Johansson; Jan Törnell; Börje Haraldsson; Jenny Nyström

Renal cell carcinoma (RCC), arising from the proximal tubule in the kidney, accounts for approximately 85% of kidney cancers and causes over 140,000 annual deaths worldwide. In the last decade, several new therapies have been identified for treatment of metastatic RCC. Although these therapies increase survival time compared to standard care, none of them has curative properties. The nephrotoxin orellanine specifically targets proximal tubular epithelial cells, leaving other organs unaffected. We therefore hypothesized that the selective toxicity of orellanine extends to clear cell RCC (ccRCC) cells since they emanate from proximal tubular cells. Orellanine would thus target both primary and metastatic ccRCC in vitro and in vivo. We found that orellanine induces dose-dependent cell death in proximal tubular cells and in all ccRCC cells tested, both primary and cell lines, with no toxicity detected in control cells. The toxic action of orellanine involve decreased protein synthesis, disrupted cell metabolism and induction of apoptosis. In nude rats carrying human ccRCC xenografts, brief orellanine treatment eliminated more than 90% of viable tumor mass compared to control rats. This identifies orellanine as a potential treatment concept for ccRCC patients on dialysis, due to its unique selective toxicity towards ccRCC.Renal cell carcinoma (RCC), arising from the proximal tubule in the kidney, accounts for approximately 85% of kidney cancers and causes over 140,000 annual deaths worldwide. In the last decade, several new therapies have been identified for treatment of metastatic RCC. Although these therapies increase survival time compared to standard care, none of them has curative properties. The nephrotoxin orellanine specifically targets proximal tubular epithelial cells, leaving other organs unaffected. We therefore hypothesized that the selective toxicity of orellanine extends to clear cell RCC (ccRCC) cells since they emanate from proximal tubular cells. Orellanine would thus target both primary and metastatic ccRCC in vitro and in vivo. We found that orellanine induces dose-dependent cell death in proximal tubular cells and in all ccRCC cells tested, both primary and cell lines, with no toxicity detected in control cells. The toxic action of orellanine involve decreased protein synthesis, disrupted cell metabolism and induction of apoptosis. In nude rats carrying human ccRCC xenografts, brief orellanine treatment eliminated more than 90% of viable tumor mass compared to control rats.This identifies orellanine as a potential treatment concept for ccRCC patients on dialysis, due to its unique selective toxicity towards ccRCC.


Scientific Reports | 2018

Amplification of the Melanocortin-1 Receptor in Nephrotic Syndrome Identifies a Target for Podocyte Cytoskeleton Stabilization

Lovisa Bergwall; Hanna Wallentin; Johannes Elvin; Peidi Liu; Roberto Boi; Carina Sihlbom; Kyle Hayes; Dale Wright; Börje Haraldsson; Jenny Nyström; Lisa Buvall

The melanocortin-1 receptor (MC1R) in podocytes has been suggested as the mediator of the ACTH renoprotective effect in patients with nephrotic syndrome with the mechanism of action beeing stabilization of the podocyte actin cytoskeleton. To understand how melanocortin receptors are regulated in nephrotic syndrome and how they are involved in restoration of filtration barrier function, melanocortin receptor expression was evaluated in patients and a rat model of nephrotic syndrome in combination with cell culture analysis. Phosphoproteomics was applied and identified MC1R pathways confirmed using biochemical analysis. We found that glomerular MC1R expression was increased in nephrotic syndrome, both in humans and in a rat model. A MC1R agonist protected podocytes from protamine sulfate induced stress fiber loss with the top ranked phoshoproteomic MC1R activated pathway beeing actin cytoskeleton signaling. Actin stabilization through the MC1R consisted of ERK1/2 dependent phosphorylation and inactivation of EGFR signaling with stabilization of synaptopodin and stressfibers in podocytes. These results further explain how patients with nephrotic syndrome show responsiveness to MC1R receptor activation by decreasing EGFR signaling and as a consequence restore filtration barrier function by stabilizing the podocyte actin cytoskeleton.


Cancer Research | 2012

Abstract LB-118: NC-001 induces apoptosis and necrosis in clear cell renal cell carcinoma in vitro and in a xenograft model in vivo

Heidi Hedman; Lisa Buvall; Ulf Nilsson; Martin Johansson; Jenny Nyström; Börje Haraldsson

Renal cancer causes over 100,000 annual deaths worldwide and constitutes about 3% of all solid cancers. The majority of renal cell carcinomas (85%), referred to as clear cell renal cell carcinoma (CCRCC), are notorious for their metastatic frequency and high resistance to conventional cancer therapies. Several new targeted therapies have been approved for treatment of metastatic renal cell carcinoma (mRCC), and although they induce a longer progression free survival, the effect on overall survival has not been statistically significant. One third of the patients with CCRCC present with advanced disease at diagnosis, and another third will develop metastases eventually, even if the original tumor is successfully removed. A metastatic form of the disease correlates with a bad poor prognosis reflected in the 5-year survival, which is less than 11% for this patient group. A fungal toxin from the Cortinarius-family, NC-001, have been shown to be specifically toxic to the proximal tubular cells in the kidney. We have shown that this sensitivity also is extended to renal cancer cells which have evolved from these. Preliminary data demonstrate that NC-001 reduces viability in five renal cancer cell lines, originating both from primary tumors and metastatic lesions. HUVEC cells seem unaffected, however at the highest dose (800µM) a reduction in viability is observed. Presently, we are evaluating the molecular mechanism behind the effect of NC-001. In vitro results show an induction of apoptosis via the intrinsic pathway, by activation of caspase-8 and further downstream by caspase-3. Caspase-9 seems to bewas unaffected. FACS analysis with Alexa Flour488 conjugated Annexin V and phosphatidylserine (PI) of SKRC-52 cells treated with 400µM for 24 hours, shows increased apoptosis and necrosis. A xenograft model of CCRCC, in radiated athymic rats, was developed to further investigate NC-0019s effects in vivo. Since NC-001 affects the proximal tubular cells in the kidney and induces severe renal failure, an automated peritoneal dialysis system for rats was developed as renal replacement therapy. The rats were treated via the dialysis solution containing 40µM NC-001 for two days. Six days later, extensive necrosis was evident in the tumors of treated rats (n=5) compared to controls (n=5). In summary, our results indicate that NC-001 induces apoptosis, mainly via the intrinsic pathway, and necrosis in SKRC-52 cells and also in solid CCRCC xenograft tumors. NC-001 has therefore potential as a curative treatment of metastatic CCRCC. The sole expected side effect of NC-001, based on hundreds of case reports of Cortinarius intoxications in the literature, is collateral loss of kidney function. While this may appear dramatic, it is surely preferable to death from metastatic cancer, especially if long term survival can be achieved. Besides, it can be well managed with dialysis, and later on, kidney transplantation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-118. doi:1538-7445.AM2012-LB-118

Collaboration


Dive into the Lisa Buvall's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jenny Nyström

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar

Ulf Nilsson

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anna Greka

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Astrid Weins

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Svetlana Andreeva

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Carina Sihlbom

University of Gothenburg

View shared research outputs
Researchain Logo
Decentralizing Knowledge